Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England

Abstract

Objective This article presents alternative parental health spillover quantification methods in the context of a randomised controlled trial comparing family therapy with treatment as usual as an intervention for self-harming adolescents, and discusses the practical limitations of those methods. Methods The trial followed a sample of 754 participants aged 11-17 years. Health utilities are measured using answers to the EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) for the adolescent and the Health Utility Index (HUI2) for one parent at baseline, 6 and 12 months. We use regression analyses to evaluate the association between the parent's and adolescent's health utilities as part of an explanatory regression model including health-related and demographic characteristics of both the adolescent and the parent. We then measure cost-effectiveness over a 12-month period as mean incremental cost-effectiveness ratios using various spillover quantification methods. We propose an original quantification based on the use of a household welfare function along with an equivalence scale to generate a health gain within the family to be added to the adolescent's quality-adjusted life-year gain. Results We find that the parent's health utility increased over the duration of the trial and is significantly and positively associated with adolescent's health utility at 6 and 12 months but not at baseline. When considering the adolescent's health gain only, the incremental cost-effectiveness ratio is £40,453 per quality-adjusted life-year. When including the health spillover to one parent, the incremental cost-effectiveness ratio estimates range from £27,167 per quality-adjusted life-year to £40,838 per quality-adjusted life-year and can be a dominated option depending on the quantification method used. Conclusion According to the health spillover quantification method considered, the incremental cost-effectiveness ratios vary from within the National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold range to not being cost-effective.

Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT

“…Children's health may have spillover effects on their parents. 122,123 Therefore, avoiding BSI may have beneficial consequences to parents' HRQoL. If this is the case, the benefits in terms of QALYs for parent and child of preventing BSI may have been underestimated and the magnitude of the necessary risk reduction for interventions to be cost-effective may have been overestimated.…”

Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness

“…A systematic literature review of CEAs of Alzheimer's disease interventions by Lin et al finds that 70% of analyses considered some family/caregiver costs or health effects, and inclusion of these effects made the incremental cost-effectiveness ratio more favorable in just under half of those studied [18]. In the evaluation of an intervention for self-harming adolescents, Tubeuf et al find an inconsistent effect of including family spillover effects on the incremental cost-effectiveness ratio, which varies with the quantification method [19]. These papers add to the small but growing body of literature suggesting that the inclusion of spillover effects may not consistently move CEA results in a more favorable direction but can also result in a less favorable economic finding for an intervention.…”

Cost-effectiveness of strategies preventing late-onset infection in preterm infants

“…The study considers the impact of LOI on the infants’ length and health-related quality of life only. Health outcomes experienced by infants and children may have spill over effects to their family and carers,38 39 which were not accounted for here.…”